MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock under...
$164,500,006
Proceeds from issuance of
common stock through...
$25,000,000
Proceeds from issuance of
common stock under...
$24,998,919
Proceeds from issuance of
common stock under...
$15,020,046
Proceeds from issuance of
common stock under...
$288,018
Proceeds from exercise of
stock options
$136,645
Net cash provided by
financing activities
$213,192,069
Canceled cashflow
$16,751,565
Net increase
(decrease) in cash and cash...
$201,207,579
Canceled cashflow
$11,984,490
something is missing
-$13,676,667
Payment of offering and
placement costs
$3,074,898
Accrued expenses
$2,366,906
Stock-based compensation
expense
$1,456,080
Other assets
-$348,790
Reduction in carrying
amount of right-of-use...
$87,274
Depreciation and
amortization expense
$78,840
Intangible asset
amortization
$7,317
Net cash used in
operating activities
-$11,977,235
Net cash (used in)
provided by investing...
-$7,255
Canceled cashflow
$4,345,207
something is missing
$58,960,024
Other segment items
$1,940,894
Net loss
-$14,964,876
Purchases of property and
equipment
$7,255
Canceled cashflow
$60,900,918
Accounts payable
-$974,893
Prepaid expenses and
other current assets
$168,824
Other liabilities
-$129,619
Lease liabilities
-$84,230
Employee-related costs
-$25,539,568
Program
expenses-IMM1104
-$23,946,023
Stock-based compensation
expense
-$7,890,500
Non-program expenses
-$7,464,608
Program expenses-Other
Programs
-$6,509,028
Program
expenses-IMM6415
-$4,097,651
Depreciation and
amortization
-$418,416
Back
Back
Cash Flow
source: myfinsight.com
Immuneering Corp (IMRX)
Immuneering Corp (IMRX)